Clinical trials
Bevacizumab clinical trials
Below are recruiting bevacizumab clinical trials, each written for real people, not researchers. We’re tracking 422 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06323382Recruiting
Liver cancer: local therapy plus immunotherapy combo
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
Beijing, Beijing MunicipalityAges 18–80 - NCT06618664RecruitingPhase 3
New triple combo vs standard therapy for advanced liver cancer
This trial tests a new combination of three drugs (SHR-8068, adebrelimab, and bevacizumab) against two standard immunotherapy combinations (sintilimab or atezolizumab plus bevacizumab) for people with advanced liver cancer who haven't had systemic treatment before. The goal is to see if the new combo works better for shrinking or controlling the cancer.
Hefei, AnhuiAges 18 years+ - NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Mobile, AlabamaAges 18 years+ - NCT04919629RecruitingPhase 2
Tested treatments for recurrent ovarian cancer with fluid buildup
This Phase 2 study tests whether adding two medicines—APL-2 plus pembrolizumab or pembrolizumab plus bevacizumab—works better than bevacizumab alone for recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also focuses on people who have symptoms from cancer-related fluid (ascites or pleural effusion).
Buffalo, New YorkAges 18 years+ - NCT03303495RecruitingPhase 3
Second-line chemo with or without bevacizumab for colon cancer
This Phase 3 study compares two treatment plans for people with metastatic colorectal cancer that got worse or caused side effects after first chemotherapy. It looks at whether adding bevacizumab (a medicine that targets blood vessels feeding tumors) improves outcomes versus using a different chemotherapy approach.
Guangzhou, GuangdongAges 18 years+ - NCT07816666RecruitingPhase 3
Maintenance treatment for relapsed ovarian cancer
This trial tests a new drug called torvutatug samrotecan, given alone or with bevacizumab, as maintenance therapy after chemotherapy for ovarian cancer that has come back. It aims to see if this treatment can help keep the cancer from growing longer.
Anchorage, AlaskaAges 18 years+ - NCT07743164RecruitingPhase 3
Raludotatug deruxtecan for PARP-inhibitor-resistant ovarian cancer
This trial tests a new drug called raludotatug deruxtecan (with or without bevacizumab) for people with ovarian cancer that has grown despite PARP inhibitor maintenance treatment. The goal is to see if this drug can shrink tumors or slow the cancer's growth.
Fountain Valley, CaliforniaAges 18 years+ - NCT07525206RecruitingPhase 3
Combination treatment for advanced colorectal cancer
This trial tests a new drug combination for colorectal cancer that has not responded to other treatments. It compares the new drug with a standard treatment to see which is more effective.
Goodyear, ArizonaAges 18 years+ - NCT06789757RecruitingPhase 2
Study of 3 drugs for liver cancer that can't be removed by surgery
This trial tests if combining two immunotherapy drugs (atezolizumab and bevacizumab) with a brain-health medicine (memantine) can help people with advanced liver cancer that isn't treatable with surgery. It aims to see if this triple therapy works better than standard options.
Fairfax, VirginiaAges 18 years+ - NCT06820463RecruitingPhase 2
Study of telisotuzumab adizutecan plus chemo for metastatic colorectal cancer
This trial tests a new drug combination for people with metastatic colorectal cancer. The study includes an experimental antibody-drug conjugate (telisotuzumab adizutecan) plus standard chemotherapy and targeted therapies, to see if it works better than current options.
Duarte, CaliforniaAges 18 years+ - NCT05503667RecruitingPhase 2
Testing EGFR drugs before lung surgery in certain stage III cancers
This trial tests whether taking furmonertinib alone, or furmonertinib plus bevacizumab, before surgery can improve outcomes for people with EGFR-mutated lung adenocarcinoma that has not spread to distant organs. It may help shrink the tumor and make surgery more effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05551208RecruitingPhase 2
Fluzoparib with bevacizumab for ovarian cancer after prior PARP therapy
This trial tests whether adding fluzoparib to bevacizumab can help control ovarian cancer that has returned after earlier PARP inhibitor (PARPi) treatment. It may help shrink tumors or slow the cancer from growing again.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05512351RecruitingPhase 2
Immunotherapy plus low-dose Avastin for recurrent oligodendroglioma
This Phase 2 trial tests an immune treatment (sintilimab, an anti–PD-1 antibody) together with low-dose bevacizumab (Avastin) to treat oligodendroglioma that has come back, including cases detected by tumor DNA in body fluid. It aims to slow or control tumor growth and help reduce symptoms by targeting both the tumor and its blood supply.
Zhengzhou, HenanAges 18 years+ - NCT05742425RecruitingPhase 2
Immunotherapy with chemo and targeted drug for colon cancer in the belly
This Phase 2 trial tests serplulimab (immunotherapy) combined with FOLFIRI chemo plus bevacizumab for colon cancer that has spread to the lining of the abdomen (peritoneal metastases). It aims to shrink these tumors and improve outcomes when surgery can’t fully remove them.
Huzhou, ZhejiangAges 18–75 - NCT05757336RecruitingPhase 2
Study drug mix for unresectable gallbladder cancer
This Phase 2 trial tests a combination of cancer medicines (gemcitabine plus albumin-paclitaxel) along with immune therapy (sintilimab) and a blood-vessel–targeting drug (bevacizumab). It’s for people with gallbladder cancer that can’t be removed by surgery, to see if the treatment controls the cancer and improves outcomes.
ShanghaiAges 18–75 - NCT05640609RecruitingPhase 1/Phase 2
Stomach cancer study using chemo plus immunotherapy plus targeted drug
This Phase 1/2 trial tests a combination treatment for advanced or metastatic stomach and food-pipe (gastroesophageal junction) cancer: a chemotherapy regimen (CapeOX) plus the immunotherapy drug sintilimab and the targeted drug bevacizumab. It aims to see how well this combination controls the cancer and how safely it can be given.
ChengduAges 18–70 - NCT06125080RecruitingPhase 2
Study of utidelone plus tirelizumab and bevacizumab for advanced triple-negative breast cancer
This trial is testing a combination of three drugs (utidelone, tirelizumab, and bevacizumab) for people with advanced or metastatic triple-negative breast cancer that has not responded to at least one prior chemotherapy. The goal is to see if this combination can shrink tumors or slow the disease.
Wuhan, HubeiAges 18–70 - NCT06156527RecruitingPhase 2
Lazertinib alone vs lazertinib plus Avastin for EGFR+ lung cancer in smokers
This trial tests if adding bevacizumab (Avastin) to lazertinib works better than lazertinib alone for advanced non-small cell lung cancer with an EGFR mutation. It is for people who have smoked at least 100 cigarettes in their lifetime.
Suwon, Gyeonggi-doAges 19 years+ - NCT06218810RecruitingPhase 2
Combination therapy for advanced MSS, RAS-mutated colorectal cancer
This trial tests a new combination of three medicines for people with a certain type of advanced colorectal cancer that has not been treated before. It aims to see if adding an immunotherapy drug (Cadonilimab) to standard chemotherapy and a targeted therapy (Bevacizumab) can help shrink tumors and delay disease progression.
ShanghaiAges 18–75 - NCT05007132RecruitingPhase 2
First-line metastatic colon or rectal cancer study with targeted drugs
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
BerlinAges 18 years+ - NCT07851025RecruitingPhase 3
Maintenance therapy for advanced ovarian cancer
This trial tests a new drug combination (torvutatug samrotecan plus bevacizumab) as maintenance therapy to help keep advanced ovarian cancer from growing after initial chemotherapy. It is for people whose tumors do not have a specific genetic change called HRD.
Tampa, FloridaAges 18 years+ - NCT06433869RecruitingPhase 2
Three-drug combination for malignant ascites from digestive cancers
This trial tests three drugs (bevacizumab, serplulimab, and rmhTNF-NC) given together to treat fluid buildup in the belly caused by digestive system cancers. It’s for people whose ascites has not improved after standard treatments.
Guangzhou, GuangdongAges 18 years+ - NCT07841574RecruitingPhase 2
Combination treatment for bile duct cancer in the liver
This trial tests a new combination of treatments for intrahepatic cholangiocarcinoma (a bile duct cancer in the liver) that cannot be surgically removed. It combines chemo directly into the liver with two drugs that boost the immune system and block blood vessel growth, hoping to shrink the tumor and help you live longer.
Guangzhou, GuangdongAges 18–75 - NCT07828015RecruitingPhase 2
Bevacizumab for hereditary hemorrhagic telangiectasia
This trial tests whether bevacizumab, a drug that blocks blood vessel growth, can reduce bleeding in people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds.
Hangzhou, ZhejiangAges 18–75
Hear when a new Bevacizumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bevacizumab?
- Yes. Clin2 currently lists 422 recruiting bevacizumab studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bevacizumab trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bevacizumab trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.